Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) FCF Margin (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed FCF Margin for 8 consecutive years, with 1177.46% as the latest value for Q1 2026.

  • Quarterly FCF Margin fell 83994.0% to 1177.46% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 942.84% through Feb 2026, down 63923.0% year-over-year, with the annual reading at 313.73% for FY2025, 567.0% up from the prior year.
  • FCF Margin for Q1 2026 was 1177.46% at Nurix Therapeutics, down from 740.09% in the prior quarter.
  • The five-year high for FCF Margin was 127.59% in Q4 2023, with the low at 1177.46% in Q1 2026.
  • Average FCF Margin over 5 years is 380.55%, with a median of 357.09% recorded in 2024.
  • The sharpest move saw FCF Margin soared 56470bps in 2023, then plummeted -83994bps in 2026.
  • Over 5 years, FCF Margin stood at 437.11% in 2022, then soared by 129bps to 127.59% in 2023, then plummeted by -269bps to 216.13% in 2024, then crashed by -242bps to 740.09% in 2025, then tumbled by -59bps to 1177.46% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 1177.46%, 740.09%, and 420.31% for Q1 2026, Q3 2025, and Q2 2025 respectively.